ConcertAI and NeoGenomics Announce Collaboration to Advance Hematological Research & Generative AI Solutions at 2024 JP Morgan Conference

ConcertAI and NeoGenomics, Inc., a leading oncology testing services company, announced a broad collaboration to advance large-scale hematological research solution to investigate real-world clinical practice and outcomes in hematological malignancies. Combining ConcertAI’s longitudinal clinical data with NeoGenomics’ comprehensive biomarkers derived from hundreds of hematological tests, the two copmanies are able to establish a robust and definitive real-world evidence (RWE) hematology solution. This is claimed to be the first population-scale hematology data set, which is both large and broad enough to minimize selection bias, to offer an actionable representation of the hematological prevalent disease in the US. The companies will be launching a hematology-focused collaborative version of ConcertAI’s Clinical Trial Optimization solution later in Q1, supporting study design and optimizing all aspects of trial planning, with multiple clinical development initiatives planned.